Genetic engineering of a hypoallergenic trimer of the major birch pollen allergen, Bet v 1
Open Access
- 24 July 2001
- journal article
- fj express-summaries
- Published by Wiley in The FASEB Journal
- Vol. 15 (11) , 2045-2047
Abstract
An estimated 100 million individuals suffer from birch pollen allergy. Specific immunotherapy, the only curative allergy treatment, can cause life‐threatening anaphylactic side effects. Here, we report the genetic engineering of a recombinant trimer consisting of three covalently linked copies of the major birch pollen allergen, Bet v 1. The trimer exhibited profoundly reduced allergenic activity but contained similar secondary structures such as Bet v 1 wild type, Bet v 1‐specific B cell and T‐cell epitopes, and induced Th1 cytokine release. As immunogen, rBet v 1 trimer induced IgG antibodies, which blocked patients’ IgE binding to Bet v 1 and related allergens. Thus, rBet v 1 trimer represents a novel hypoallergenic vaccine prototype for treatment of one of the most frequent allergy forms.Keywords
Funding Information
- Austrian Science Fund (Y078GEN)
This publication has 33 references indexed in Scilit:
- Comparison of genetically engineered hypoallergenic rBet v 1 derivatives with rBet v 1 wild‐type by skin prick and intradermal testing: results obtained in a French populationClinical & Experimental Allergy, 2000
- Quantitative IgE inhibition experiments with purified recombinant allergens indicate pollen-derived allergens as the sensitizing agents responsible for many forms of plant food allergyJournal of Allergy and Clinical Immunology, 2000
- Signalling through the high-affinity IgE receptor FcεRINature, 1999
- Skin test evaluation of genetically engineered hypoallergenic derivatives of the major birch pollen allergen, Bet v 1: Results obtained with a mix of two recombinant Bet v 1 fragments and recombinant Bet v 1 trimer in a Swedish population before the birch pollen season☆☆☆★Journal of Allergy and Clinical Immunology, 1999
- Role of interleukin 10 in specific immunotherapy.Journal of Clinical Investigation, 1998
- Conversion of the major birch pollen allergen, Bet v 1, into two nonanaphylactic T cell epitope-containing fragments: candidates for a novel form of specific immunotherapy.Journal of Clinical Investigation, 1997
- IgE-Mediated Allergen Presentation via Fc Epsilon Rl on Antigen-Presenting CellsInternational Archives of Allergy and Immunology, 1997
- FcεRI on antigen-presenting cellsCurrent Opinion in Immunology, 1996
- T cell clones specific for Bet v I, the major birch pollen allergen, crossreact with the major allergens of hazel, Cor a I, and alder, Aln g IMolecular Immunology, 1993
- Profilins constitute a novel family of functional plant pan-allergens.Journal of Experimental Medicine, 1992